Water-based components

Abstract

The present invention provides aqueous compositions that maintain a certain level of water content and viscosity when stored at room temperature. [Solution] An aqueous composition containing proteoglycan, ascorbic acid derivative, ellagic acid, coenzyme Q10, and a nonionic surfactant.

Description

Technical Field

[0001] The present invention relates to a novel use of proteoglycan (such as skin external preparations such as cosmetics and quasi-drugs).

Background Art

[0002] It is considered that a composition containing proteoglycan or the like has an effect of improving the skin (such as reducing porphyrin and improving skin moisturization) (Patent Document 1).

[0003] There is a demand for a skin-applying composition that has a highly transparent appearance and has a moist feeling characteristic of an oil agent when applied to the skin, and provides a good spreadability and the like (Patent Document 1).

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Patent Document 2

Summary of the Invention

Problems to be Solved by the Invention

[0005] The present inventors newly provide an aqueous composition that maintains a certain level of water content and viscosity during storage at normal temperature (JIS Z 8703-1983).

Means for Solving the Problems

[0006] As a result of intensive studies to solve the above problems, the present inventors have found that, in an aqueous composition containing proteoglycan, by containing a predetermined component, a certain level of water content and viscosity can be maintained during storage at normal temperature (JIS Z 8703-1983, temperature from 15°C to 35°C). That is, the present invention includes the following embodiments.

[0007] [1] An aqueous composition containing a proteoglycan, an ascorbic acid derivative, ellagic acid, coenzyme Q10, and a nonionic surfactant. [2] An aqueous composition containing a proteoglycan, arbutic acid, tranexamic acid, a heparin-like substance, and a nonionic surfactant. [3] The composition according to [1] or [2] further comprising arbutin, tranexamic acid, heparinoid, ceramide, placenta extract, linoleic acid, dipotassium glycyrrhizinate and / or NMN. [4] A composition according to any one of [1] to [3] for external use on the skin. [Effects of the Invention]

[0008] According to the present invention, it is possible to provide aqueous compositions that maintain a certain level of water content and viscosity when stored at room temperature (JIS Z 8703-1983).

[0009] The following provides a detailed explanation of this disclosure, including examples. Unless otherwise specified, each disclosure may refer to the explanations of other disclosures.

[0010] <Definition> (derived from) In the specification of this application, the phrase "derived from" is used with the intention of encompassing (1) to (3) below. (1) It is purified, (2) Being isolated, and / or (3) Modification [this includes low molecular weight treatment and high molecular weight treatment (polymerization)] or alteration.

[0011] (Proteoglycan) "Proteoglycan" refers to a molecule (glycoprotein) in which a protein (core protein) and a glycosaminoglycan (GAG, also called "polysaccharide" or "sugar chain") are covalently bonded. Proteoglycans exist, for example, as extracellular matrix in skin, organs, and cartilage. Glycosaminoglycans are generally known as long-chain sugar chains that do not have a branched structure. Examples of the aforementioned proteoglycans include aggrecan, versican, decorin, testican, breakican, biglycan, serglycin, syndecan, perlecan, dystroglycan, agrin, claustrin, glypican, lumican, keratocan, and neurocan. These proteoglycans can be classified, for example, into chondroitin sulfate proteoglycans, dermatan sulfate proteoglycans, heparan sulfate proteoglycans, or keratan sulfate proteoglycans depending on the type of GAG bound to the protein.

[0012] Examples of the aforementioned GAGs include chondroitin, chondroitin sulfate, dermatan sulfate (chondroitin sulfate B), heparan sulfate, heparin, and keratan sulfate. Examples of chondroitin include O-type sugar chains with a disaccharide structure of glucuronic acid and acetylgalactosamine as the main disaccharide structure, and iO-type sugar chains with a disaccharide structure of iduronic acid and acetylgalactosamine as the main structure (hereinafter also referred to as "chondroitin sulfate O" and "chondroitin sulfate iO," respectively). Chondroitin sulfate has a structure in which a sulfate group is added to a sugar chain in which the disaccharides of glucuronic acid and acetylgalactosamine are repeated. Examples of chondroitin sulfate include glucuronic acid and acetylgalactosamine tetrasulfate. Examples include chondroitin sulfate A (Type A), which has a disaccharide structure with ioduronic acid and acetylgalactosamine 4-sulfate as its main disaccharide structure; chondroitin sulfate iA (Type iA), which has a disaccharide structure with ioduronic acid and acetylgalactosamine 6-sulfate as its main disaccharide structure; chondroitin sulfate C (Type C), which has a disaccharide structure with glucuronic acid and acetylgalactosamine 6-sulfate as its main disaccharide structure; and chondroitin sulfate iC (Type iC), which has a disaccharide structure with ioduronic acid and acetylgalactosamine 6-sulfate as its main disaccharide structure. Each chondroitin sulfate has, for example, the disaccharide structure shown in Figure 1 as its main disaccharide structure.

[0013] The PG derived from salmon nasal cartilage is PG obtained by extraction from salmon nasal cartilage. Here, salmon refers to fish belonging to the genus Oncorhynchus, for example, but preferably salmon with the scientific name "Oncorhynchus keta" is selected from the viewpoint of efficiently regulating the immune response. The proteoglycan contained in the composition of the present invention is prepared, for example, by the method described in the publication (Japanese Patent Publication No. 6317053). Furthermore, the proteoglycan content in the composition (1g) containing the composition of the present invention is preferably at a lower limit of 0.005% or more in the composition, for example from the viewpoint of effectively exhibiting the desired effect.

[0014] The proteoglycans used in this invention, such as PG derived from salmon nasal cartilage, can be produced by methods described in, for example, Japanese Patent Publications (Japanese Patent No. 6875701, Japanese Patent No. 6317053, and Japanese Patent No. 7295572).

[0015] Commercially available PG products include, for example, salmon nasal cartilage-derived PG, such as Proteoglycan IPC (Ichimaru Pharcos) and Proteoglycan F (Ichimaru Pharcos). In the following examples, Proteoglycan IPC (water: 69.3%, 1,3-butylene glycol: 29.7%, water-soluble proteoglycan: 1%) was used.

[0016] (Ascorbic acid derivative) In the present invention, as an ingredient in a topical skin preparation in the field of pharmaceuticals, quasi-drugs, or cosmetics The ascorbic acid derivative used can be used.

[0017] Ascorbic acid derivatives are not particularly limited as long as they can be used in cosmetics, pharmaceuticals, etc. Examples include ascorbic acid ester salts such as L-ascorbic acid-2-phosphate sodium, L-ascorbic acid-2-phosphate magnesium, L-ascorbic acid-2-sulfate sodium, and L-ascorbic acid-2-sulfate magnesium; L-ascorbic acid glucosides such as L-ascorbic acid-2-glucoside and L-ascorbic acid-5-glucoside; L-ascorbic acid tetra fatty acid esters such as L-ascorbic acid tetraisopalmitate and L-ascorbic acid tetralaurate; and L-ascorbic acid ethers such as 3-O-ethylascorbic acid. Of these, L-ascorbic acid glucosides are preferred, and L-ascorbic acid 2-glucoside is particularly preferred.

[0018] In this invention, AA2G (L-ascorbic acid 2-glucoside, Ichimaru Pharcos) was used as the ascorbic acid derivative.

[0019] (Ellagic acid) Ellagic acid is a compound with a polyphenol structure represented by the molecular formula C 14 H6O8. It is known that most of the ellagic acid contained in plants exists in a state where a sugar called ellagitannin is bound. Examples of commercially available ellagic acid include pomegranate ellagic acid (Sabinsa Japan Corporation), ellagic acid dihydrate (Wako Pure Chemical Industries), ellagic acid (Kanto Chemical), and the like.

[0020] (Coenzyme Q10) Coenzyme Q10 refers to 2,3-dimethoxy-5-methyl-6-polyprenyl-1,4-benzoquinone in which the number of isoprene units in the side chain is 10, and it is a ubiquinone unique to humans. In the Japanese Pharmacopoeia, this coenzyme Q10 is described as "ubidecarenone", and as a food additive, it is called "coenzyme Q10", and as a cosmetic raw material, it is called "ubiquinone". Ubiquinone is an essential coenzyme for energy production in mitochondria. Also, ubiquinone is an important substance in the body as an antioxidant, and its effectiveness in heart disease, hypertension, and rheumatic valvular disease, which is considered to be due to improved cell metabolism, has been confirmed. In addition, ubiquinone is said to exhibit effects such as improving rough skin in cosmetics (Japanese Patent No. 5180556).

[0021] Note that ubiquinone is poorly water-soluble and highly crystalline, and generally, formulation is difficult. For example, it dissolves well in non-polar hydrocarbons such as ether and hexane, but is extremely difficult to dissolve in other solvents. Although many methods have been proposed to disperse ubiquinone in the system using various auxiliaries such as surfactants and encapsulating agents, such methods have many formulation restrictions, low physical stability, and separation or precipitation occurs upon long-term storage, which easily causes problems as a product. To ensure or improve the effect of ubiquinone formulations, it is considered effective to increase the concentration of ubiquinone in the formulation. However, due to the poor water-solubility and crystallinity as described above, it is considered difficult to formulate a preparation that ensures a sufficient concentration in the most commonly used aqueous agent system (Japanese Patent No. 5180556).

[0022] (Arbutin) The arbutin used in the present invention is not particularly limited and may be α-type or β-type. Furthermore, the method for producing arbutin is not particularly limited and may be extracted from natural products or obtained synthetically. When arbutin is used in the composition of the present invention, the arbutin content is preferably 0.001 to 20% by mass, more preferably 0.002 to 10% by mass, and even more preferably 0.005 to 5% by mass, considering efficacy and solubility. In the following examples, α-type arbutin was used.

[0023] (Tranexamic acid) Tranexamic acid is an abbreviation for trans-4-aminomethylcyclohexane-1-carboxylic acid. Tranexamic acids include tranexamic acid, tranexamic acid salts, tranexamic acid esters, tranexamic acid amides, and polymers of tranexamic acid. Examples of salts in tranexamic acid salts include metal salts such as sodium salts, potassium salts, and magnesium salts; and inorganic salts such as hydrochloride salts, phosphate salts, and sulfate salts. Examples of esters in tranexamic acid esters include vitamin esters such as vitamin A esters, vitamin E esters, and vitamin C esters, and alkyl esters. Examples of amides in tranexamic acid amides include methylamide.

[0024] In the present invention, tranexamic acid also includes derivatives of tranexamic acid. Examples of derivatives of tranexamic acid include tranexamic acid dimers (trans-4-(trans-4-aminomethylcyclohexanecarbonyl)aminomethylcyclohexanecarboxylic acid hydrochloride), esters of tranexamic acid and hydroquinone (trans-4-aminomethylcyclohexanecarboxylic acid 4'-hydroxyphenyl ester), esters of tranexamic acid and gentisic acid (2-(trans-4-aminomethylcyclohexylcarbonyloxy)-5-hydroxybenzoic acid and its salts), amides of tranexamic acid (trans-4-aminomethylcyclohexanecarboxylic acid methylamide and its salts, trans-4-acetylaminomethylcyclohexanecarboxylic acid and its salts, trans-4-(p-methoxybenzoyl)aminomethylcyclohexanecarboxylic acid and its salts, trans-4-guanidinomethylcyclohexanecarboxylic acid and its salts, etc.).

[0025] There are no particular limitations on the amount of one or more tranexamic acid (including derivatives of tranexamic acid) selected from those contained in the composition of the present invention. However, in order to achieve the desired effect, the amount of tranexamic acid relative to the total amount of the composition is generally preferably 0.001% by weight or more, more preferably 0.01% by weight or more, and even more preferably 0.1% by weight or more. Furthermore, considering the desired effect, etc. (for example, the fact that even if a certain amount is added, a substantial increase in effect cannot be expected, and that it tends to become difficult to incorporate in the formulation of topical skin preparations), the amount of tranexamic acid relative to the total amount of the composition is generally preferably 20% by weight or less, more preferably 10% by weight or less, and even more preferably 7% by weight or less.

[0026] (Heparin-like substance) Heparin-like substances refer to a general term for polysulfated mucopolysaccharides such as chondroitin polysulfate, and preferably have an average of 0.5 to 5 sulfate groups, more preferably an average of 0.6 to 3 sulfate groups, per monosaccharide molecule constituting the mucopolysaccharide. More specifically, heparin-like substances contain heparin, chondroitin sulfate D and chondroitin sulfate E, which are called chondroitin polysulfates. Heparin-like substances can be obtained by sulfated mucopolysaccharides, or by extraction and purification using an aqueous carrier from the internal organs, including the bronchi, of animals such as cattle and pigs, and then sulfated as necessary. Since such heparin-like substances have been developed as pharmaceutical and cosmetic ingredients, commercially available products can also be used. In the composition of the present invention, heparin-like substances listed in the Japanese Pharmacopoeia (Standards for Non-Official Drugs) are preferably used.

[0027] (Nonionic surfactant) Surfactants are molecularly designed to exhibit numerous functions (activity), and there are four main types. Three types of ionic surfactants dissociate into ions (charged atoms or groups of atoms) when dissolved in water, and one nonionic surfactant does not ionize, making a total of four types (Japan Surfactant Industry Association website, URL: https: / / jp-surfactant.jp / surfactant / nature / index.html). Examples of nonionic surfactants include fatty acid sorbitan esters, polyoxyethylene fatty acid sorbitan (polysorbate 80), polyoxyethylene higher alcohol ethers, poly(oxyethylene-oxypropylene) higher alcohol ethers, polyoxyethylene fatty acid esters, polyoxyethylene alkylphenols, polyoxyethylene alkylamines, and polyoxyethylene-polyoxypropylene block polymers. Examples of amphoteric surfactants include dimethylalkyl betaine and alkylamide betaine. In the following examples, polysorbate 80 was used as the nonionic surfactant.

[0028] (others) The present invention may contain butylene glycol (1,3-butylene glycol) as long as it does not hinder the effects of the present invention, from the viewpoint of stability and other factors.

[0029] The composition of the present invention preferably contains 1% by mass or less of a preservative relative to its total mass. Here, the preservative is not particularly limited as long as it is a preservative added to the topical skin preparation described later, but there are problems such as causing skin irritation or stickiness when added to topical skin preparations, and it is desirable to reduce the amount used as much as possible. The preparation of this embodiment has a high sugar content, so the growth of microorganisms is suppressed, and it is not necessary to add a preservative when stored at low temperatures, but the desired preservative properties of the liquid can be ensured even when stored at room temperature by using a low concentration of a preservative. Therefore, it is possible to manufacture a topical preparation composition that can be used without causing irritation even by people with sensitive skin who experience skin irritation with conventional amounts of preservatives. Accordingly, there is no lower limit to the concentration when adding a preservative, and it is sufficient if it is above 0% by mass. The upper limit is 1% by mass, preferably 0.5% by mass, and more preferably 0.1% by mass. Examples of preservatives that have preservative effects at these low concentrations are parabens, benzoic acid and its salts, etc. In the following examples, a predetermined amount of phenoxyethanol was used to exhibit preservative effects, etc.

[0030] The water used is not particularly limited, as long as it is the type commonly used in cosmetics, etc. In addition to water, purified water, hot spring water, deep-sea water, or steam-distilled water from plants may also be used, and one or more of these may be appropriately selected and used as needed.

[0031] (Composition for external use on the skin) In the present invention, compositions for external use on the skin, such as cosmetics, topical pharmaceuticals, and quasi-drugs, are prepared in the form of general topical skin preparations and put into practical use, for example, using a suitable pharmaceutical carrier that is pharmaceutically acceptable.Examples of such formulation carriers include humectants such as glycerin, petrolatum, urea, hyaluronic acid, and heparin; PABA derivatives (para-aminobenzoic acid, Escalol 507, etc.), cinnamic acid derivatives (Neo-Heliopan, Parsol MCX, Sunguard B, etc.), salicylic acid derivatives (octyl salicylate, etc.), benzophenone derivatives (ASL-24, ASL-24S, etc.), dibenzoylmethane derivatives (Parsol A, Parsol DAM, etc.), heterocyclic derivatives (Tinuvin derivatives, etc.), and ultraviolet absorbers and scatterers such as titanium dioxide; disodium edetate, methyl edetate Metal sequestering agents such as sodium, citric acid, sodium citrate, tartaric acid, sodium tartrate, lactic acid, malic acid, sodium polyphosphate, sodium metaphosphate, and gluconic acid; sebum inhibitors such as salicylic acid, sulfur, caffeine, and tannins; disinfectants such as benzalkonium chloride, benzethonium chloride, and chlorhexidine gluconate; anti-inflammatory agents such as diphenhydramine hydrochloride, tranexamic acid, guaiazulene, azulene, allantoin, hinokitiol, glycyrrhizic acid and its salts, glycyrrhizic acid derivatives, and glycyrrhetinic acid; vitamins Vitamins such as vitamin A, B vitamins (B1, B2, B6, B12, B15), folic acid, nicotinic acid derivatives, pantothenic acid derivatives, biotin, vitamin C, vitamin D vitamins (D2, D3), vitamin E, ubiquinone derivatives, and vitamin K (K1, K2, K3, K4); amino acids and their derivatives such as aspartic acid, glutamic acid, alanine, lysine, glycine, glutamine, serine, cysteine, cystine, tyrosine, proline, arginine, and pyrrolidone carboxylic acid; retinol, tocopherol acetate, magnesium ascorbate phosphate, kojic acid, and placenta. Whitening agents such as extracts (e.g., placenta extract derived from animals such as pigs); antioxidants such as butylhydroxytoluene, butylhydroxyanisole, and propyl gallate; astringents such as zinc chloride, zinc sulfate, zinc carbolic acid, zinc oxide, and potassium aluminum sulfate; sugars such as glucose, fructose, maltose, sucrose, trehalose, erythritol, mannitol, xylitol, and lactitol; and other specified plant extracts, as well as oily components, surfactants other than those mentioned above (ionic surfactants), thickeners, alcohols, powder components, and pigments.These can be supplied by performing processing according to the type and form of product to be added (for example, a combination of processes such as crushing, milling, washing, hydrolysis, fermentation, purification, pressing, extraction, fractionation, filtration, drying, powdering, granulation, dissolution, sterilization, pH adjustment, deodorization, decolorization, etc., as arbitrarily selected from various materials).

[0032] Furthermore, by combining the various cosmetic and medicinal effects of each known raw material, it is possible to create products with multifunctional properties.

[0033] Specific examples of topical skin preparations include cosmetic creams, lotions, toners, face masks, skin milks (emulsifiers), gels, powders, lip balms, lipsticks, under-makeup products, foundations, sunscreens, bath products, body washes, body rinses, soaps, cleansing foams, ointments, patches, gels, aerosols, and the like.

[0034] (Beauty method) Another embodiment of the present invention relates, for example, to a beauty method using the above-described composition for external skin application. The beauty method of this embodiment is characterized by improving the skin's resident microbiota and skin condition by applying the above-described composition for external skin application to a subject. The application method is, for example, to apply it to the skin of a desired area of ​​the subject. Application to the skin may be performed, for example, once or multiple times a day. This can be appropriately selected depending on the type of composition. Generally, when applied as a composition prepared as a lotion, emulsion, gel, cream, or ointment, it is preferable to apply it to the skin, such as the face, about once or twice a day. The composition for external skin application of the present invention can also be used as a cosmetic, for example, and can be applied to lotions, emulsions, serums, creams, liquid foundations, powder foundations, lipsticks, etc. In this embodiment, the beauty method includes not only methods performed personally, but also those provided as a cosmetic formulation tailored to the customer when providing beauty-related products, and provided by cosmetic salespeople or estheticians other than doctors. It also includes those provided as a method of use for beauty-related products in product instructions (package inserts, etc.).

[0035] (Oily oiliness) Excess sebum and sweat that rise to the surface of the skin normally function as a protective barrier, but it is thought that excessive secretion due to some cause results in shininess. It is thought that hormonal imbalances, an unbalanced diet, and ultraviolet rays can also cause it.

[0036] (pores) Pores, whose openings to the skin surface widen with age, are characterized by a reduction in the protruding edges of the uneven structure of the skin surface, resulting in a mortar-shaped, sloping surface from the edge of the opening to the central bottom. There is no specific age at which this occurs; rather, individuals may notice that their pores have become more noticeable with age. Pores vary from person to person, and aging, in particular, can cause the openings to widen on the skin surface, resulting in a mortar-shaped appearance, with a longer sloping portion and a wider bottom (Japanese Patent Publication No. 2023-069112).

[0037] Facial pores are present in everyone, but how they appear, and whether or not people are concerned about them, varies greatly from person to person. However, for women, for example, noticeable pores are not seen as a positive thing, but rather as a negative, and there is a demand for effective makeup methods that make pores less visible (Japanese Patent Publication No. 2023-069112).

[0038] As mentioned above, whether or not pores are noticeable varies from person to person, but one of the contributing factors is aging. Generally, with age, the opening of the pore on the skin surface tends to widen morphologically, and this is one of the reasons why pores become more noticeable with age. In younger people, the pore morphology is thought to consist of relatively cylindrical depressions that occur independently, but with age, the opening of the opening diminishes the edges of the convex structure in the uneven structure of the skin surface, resulting in the depressions becoming more noticeable. Morphologically comparing the pores of both age groups, in younger people, the skin surface is described as having a "fine texture," and the pores themselves tend to be small and inconspicuous, or if present, they tend to be vertically cylindrical. In contrast, with age, the opening of the pore on the skin surface widens, and it is thought that it takes on a slope towards the bottom of the center, like the slope of a mortar. Thus, since the morphology of pores differs with age, there is no single method for simply concealing pores, and the most suitable makeup methods for this purpose also differ (Japanese Patent Publication No. 2023-069112).

[0039] The present invention will now be described in more detail with reference to examples, but the present invention is not limited in any way to these examples. In the following examples, the unit % in the numerical values ​​indicating the amount of each component added means mass %. [Examples]

[0040] [Preparation of Examples 1 to 4 and Comparative Examples 1 to 4] Aqueous compositions of Examples 1 to 4 with the compositions shown in Table 1 and aqueous compositions of Comparative Examples 1 to 4 with the compositions shown in Table 2 were prepared. The preparation methods are as follows.

[0041] (Manufacturing method) The compositions for groups A and F were prepared as follows: Composition of Group A: The following components were uniformly dissolved and mixed. • Placenta extract: Falcorex PC-1, Ichimaru Falcos • Linoleic acid: Fujifilm Wako Pure Chemical Industries • Dipotassium glycyrrhizinate: Hiroki • NMN:β-NMN • Swertia japonica extract: Swertianin, Ichimaru Falcos • Retinyl palmitate: Palmitate 1000E, Riken Vitamin • Polysorbate 80: EMALEX ET-8020, Nippon Emulsion Phenoxyethanol ·water

[0042] Composition of Group B: The following components were uniformly dissolved and mixed. • Niacinamide (Nicotinamide): Kishida Chemical Co., Ltd. • Allantoin: Wako Pure Chemical Industries • dl-α-tocopherol acetate: Riken E Acetate 960, Riken Vitamin • Sodium hyaluronate: Bio-hyaluronate sodium 1% solution (MP-PE) N, Ichimaru Falcos • Hydrolyzed elastin: Elastocean 4% PE, Koken • Polysorbate 80: EMALEX ET-8020, Nippon Emulsion Phenoxyethanol ·water

[0043] Composition of Group C: The following components were uniformly dissolved and mixed. • Ascorbic acid derivatives: AA2G, Ichimaru Falcos • Ellagic acid: Fujifilm Wako Pure Chemical Industries Coenzyme Q10: Pharmacopoeia / Mitsubishi Gas Chemical • Octopirox: Piroctone olamine, Tokyo Chemical Co., Ltd. • Collagen: Falconix CTP-F (BG), Ichimaru Falcos • Polysorbate 80: EMALEX ET-8020, Nippon Emulsion Phenoxyethanol ·water • 0.1% sodium hydroxide aqueous solution (0.1% Na hydroxide) • 0.2% sodium hydroxide aqueous solution (0.2% Na hydroxide)

[0044] Composition of Group D: The following components were uniformly dissolved and mixed. Arbutin: α-arbutin • Tranexamic acid: Tranexamic acid, Human Dongting Phermaceutical • Heparin-like substances • Carrots: Shin Hong Gini Herring LV, Ichimaru Falcos • Ceramide: Water-soluble ceramide RC, Ichimaru Falcos • Polysorbate 80: EMALEX ET-8020, Nippon Emulsion Phenoxyethanol ·water

[0045] Composition of Group E: The following components were uniformly dissolved and mixed. ·water 1,3-butylene glycol Glycerin Phenoxyethanol

[0046] Group F: The following two items were prepared. • Proteoglycan IPC (Ichimaru Falcos): As mentioned above, it contains water, 1,3-butylene glycol, and water-soluble proteoglycan. ·water

[0047] The compositions from groups A to E were uniformly dissolved and mixed at room temperature using predetermined amounts of the compositions to obtain the compositions shown in Table 1. After this dissolution and mixing, predetermined amounts of proteoglycan IPC from group F or water were added at room temperature and dissolved and mixed to prepare the compositions of the examples shown in Table 1 and the comparative examples shown in Table 2.

[0048] [Table 1]

[0049] [Table 2]

[0050] (Evaluation of the composition) The evaluation of the examples described in Table 1 and the comparative examples described in Table 2 (viscosity, sebum shine, pore improvement) was performed as follows. The comparisons were made between Example 1 and Comparative Example 1, between Example 2 and Comparative Example 2, between Example 3 and Comparative Example 3, and between Example 4 and Comparative Example 4. The evaluation results are shown in Table 3.

[0051] (Evaluation of viscosity) The creator of each example composition (one healthy person between their 20s and 50s) judged the composition based on its appearance and feel when the F group described above was added, and on its appearance and feel after 7 days of storage at room temperature with the addition of the F group. In Table 3, ○ indicates a higher viscosity compared to the comparative example, and △ indicates no change between the example and the comparative example. As shown in Table 3, a certain improvement in viscosity was confirmed in all examples compared to the comparative example.

[0052] (Sensory evaluation: Oily shine, enlarged pores, noticeable pores) Panelists (four healthy individuals aged 20 to 50) evaluated the physical sensations and appearance (physical sensations, etc.) when the compositions containing the F group described above were applied to designated areas on their faces or arms. In Table 3, ○ indicates that there was a noticeable difference in physical sensations compared to the comparative example, and △ indicates that there was no change between the example and the comparative example. As shown in Table 3, noticeable differences in physical sensations were particularly observed in Examples 1, 2, and 3.

[0053] [Table 3]

[0054] Although embodiments of the present invention (including examples) have been described above with reference to the drawings, the specific configuration of the present invention is not limited thereto, and any design changes, etc., that do not depart from the spirit of the present invention are still included. [Industrial applicability]

[0055] This technology can be used to provide aqueous compositions that maintain a certain level of water content and viscosity when stored at room temperature (JIS Z 8703-1983), among other things.

Claims

1. An aqueous composition containing proteoglycan, ascorbic acid derivative, ellagic acid, coenzyme Q10, and a nonionic surfactant.

2. An aqueous composition containing proteoglycan, arbutic acid, tranexamic acid, heparinoid, and a nonionic surfactant.

3. The composition according to claim 1 or 2, further comprising arbutin, tranexamic acid, heparin-like substance, ceramide, placenta extract, linoleic acid, dipotassium glycyrrhizinate and / or NMN.

4. The composition according to claim 1 or 2 for external use on the skin.

Images